In VivoBiopharma financings during the second quarter of 2022 reached $12.5bn. The largest was by Blueprint Medicines Corporation (precision therapies for cancer and blood disorders) through an arrangement
ScripThe series C venture capital round that Tessera Therapeutics announced on 19 April – totaling more than $300m, the company said – shows that investors continue to be willing to invest large sums in